Key result
Glibenclamide significantly attenuated adenosine-induced coronary dilatation, increasing the 50% effective dose from 0.13 to 1.1 mumol/kg (P<0.001), and inhibited bradycardia and hypotension in dogs.
Why the study?
Does glibenclamide attenuate adenosine-induced bradycardia, hypotension, and coronary vasodilatation in dogs?
Population
Anesthetized dogs with either combined beta-adrenergic and muscarinic receptor blockade or bilateral…
Comparison
Glibenclamide prior to adenosine administration vs Control state
Design
Preclinical
Authors
Loading...
These canine findings should not alter adenosine use in patients; leaves open KATP channel mediation of coronary responses in humans.
Does glibenclamide attenuate adenosine-induced bradycardia, hypotension, and coronary vasodilatation in dogs?
Absolute Event Rate: 1.1% vs 0.13%
p-value: p=<0.001
Glibenclamide attenuates adenosine-induced bradycardia, hypotension, and coronary vasodilatation in dogs, suggesting involvement of ATP-sensitive K+ channels in these responses.
Belloni et al. (1991) studied this question. Glibenclamide vs. Control state was evaluated on 50% effective dose for adenosine-induced coronary dilatation (p=<0.001). Glibenclamide significantly attenuated adenosine-induced coronary dilatation, increasing the 50% effective dose from 0.13 to 1.1 mumol/kg (P<0.001), and inhibited bradycardia and hypotension in dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: